JP6865585B2 - 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 - Google Patents

成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 Download PDF

Info

Publication number
JP6865585B2
JP6865585B2 JP2016559286A JP2016559286A JP6865585B2 JP 6865585 B2 JP6865585 B2 JP 6865585B2 JP 2016559286 A JP2016559286 A JP 2016559286A JP 2016559286 A JP2016559286 A JP 2016559286A JP 6865585 B2 JP6865585 B2 JP 6865585B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016559286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508475A (ja
JP2017508475A5 (enExample
Inventor
ヴィシュフーセン，ヨルク
ユンケル，マルクス
シェファー，ティナ
ピュリンガー，ディルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of JP2017508475A publication Critical patent/JP2017508475A/ja
Publication of JP2017508475A5 publication Critical patent/JP2017508475A5/ja
Priority to JP2021064572A priority Critical patent/JP7607498B2/ja
Application granted granted Critical
Publication of JP6865585B2 publication Critical patent/JP6865585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
JP2016559286A 2014-03-26 2015-03-26 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 Active JP6865585B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021064572A JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB1405475.3 2014-03-26
GB1405477.9 2014-03-26
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064572A Division JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Publications (3)

Publication Number Publication Date
JP2017508475A JP2017508475A (ja) 2017-03-30
JP2017508475A5 JP2017508475A5 (enExample) 2018-05-17
JP6865585B2 true JP6865585B2 (ja) 2021-04-28

Family

ID=52745885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016559286A Active JP6865585B2 (ja) 2014-03-26 2015-03-26 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Country Status (22)

Country Link
US (6) US20170204174A1 (enExample)
EP (3) EP3122775B1 (enExample)
JP (3) JP6865585B2 (enExample)
KR (1) KR102520978B1 (enExample)
CN (1) CN106536553B (enExample)
AU (2) AU2015238264B2 (enExample)
BR (1) BR122023027559A2 (enExample)
CY (1) CY1122456T1 (enExample)
DK (2) DK3653644T5 (enExample)
ES (2) ES2763859T3 (enExample)
FI (1) FI3653644T3 (enExample)
HR (2) HRP20231514T1 (enExample)
HU (2) HUE047398T2 (enExample)
IL (2) IL248038B (enExample)
LT (2) LT3653644T (enExample)
NZ (1) NZ724649A (enExample)
PL (2) PL3122775T3 (enExample)
PT (2) PT3653644T (enExample)
RS (1) RS59700B1 (enExample)
SI (1) SI3122775T1 (enExample)
SM (1) SMT202000064T1 (enExample)
WO (1) WO2015144855A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3122775B1 (en) 2014-03-26 2019-11-13 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
JP6858181B2 (ja) * 2015-10-02 2021-04-14 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５
JP6925326B2 (ja) 2015-10-02 2021-08-25 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
JP7059494B2 (ja) * 2016-07-06 2022-04-26 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門を通過するヒト化抗体及びその使用
MA46523A (fr) * 2016-10-12 2019-08-21 Janssen Biotech Inc Procédés de criblage de modulateurs d'une activité biologique de type gdf15
CA3045700A1 (en) * 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
CA3109905A1 (en) 2018-08-20 2020-02-27 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
EP4384545A1 (en) 2021-08-10 2024-06-19 BYOMass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
CN116535503A (zh) * 2022-01-26 2023-08-04 康源博创生物科技(北京)有限公司 抗生长分化因子15的抗体分子及其应用
AU2022437929A1 (en) * 2022-01-26 2024-08-08 Yunnan Baiyao Group Co., Ltd. Antibody molecule against growth and differentiation factor 15 and use thereof
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
TW202547861A (zh) * 2024-04-23 2025-12-16 大陸商勁方醫藥科技(上海)股份有限公司 抗gdf-15抗體及其應用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
ATE348164T1 (de) 1999-05-17 2007-01-15 Bioph Biotech Entw Pharm Gmbh Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
AU2005205533B2 (en) * 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
ES2518865T3 (es) 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
EP2783698A1 (en) * 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
PT2900263T (pt) * 2012-09-26 2019-07-29 Univ Wuerzburg J Maximilians Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15)
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP3122775B1 (en) 2014-03-26 2019-11-13 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Also Published As

Publication number Publication date
EP3122775B1 (en) 2019-11-13
US11760795B2 (en) 2023-09-19
EP3653644A1 (en) 2020-05-20
EP3653644B1 (en) 2023-11-15
ES2763859T3 (es) 2020-06-01
US20180298091A1 (en) 2018-10-18
AU2020260440A1 (en) 2020-11-26
FI3653644T3 (fi) 2023-12-12
US10604565B2 (en) 2020-03-31
IL276405A (en) 2020-09-30
WO2015144855A1 (en) 2015-10-01
JP2017508475A (ja) 2017-03-30
IL248038A0 (en) 2016-11-30
US20260008841A1 (en) 2026-01-08
AU2015238264A1 (en) 2016-10-20
PT3122775T (pt) 2019-12-26
ES2965626T3 (es) 2024-04-16
US20200308265A1 (en) 2020-10-01
IL276405B (en) 2021-07-29
JP2021119138A (ja) 2021-08-12
US20200308264A1 (en) 2020-10-01
US20170204174A1 (en) 2017-07-20
PL3122775T3 (pl) 2020-05-18
US20230382987A1 (en) 2023-11-30
PT3653644T (pt) 2023-12-19
CA2943694A1 (en) 2015-10-01
KR102520978B1 (ko) 2023-04-11
PL3653644T3 (pl) 2024-03-04
DK3653644T5 (da) 2024-08-26
AU2020260440B2 (en) 2024-03-21
HRP20200034T1 (hr) 2020-03-20
SMT202000064T1 (it) 2020-03-13
BR122023027559A2 (pt) 2024-01-30
LT3122775T (lt) 2020-02-10
RS59700B1 (sr) 2020-01-31
SI3122775T1 (sl) 2020-02-28
CY1122456T1 (el) 2021-01-27
JP2023098966A (ja) 2023-07-11
EP4316596A2 (en) 2024-02-07
BR112016022013A2 (pt) 2017-10-31
JP7607498B2 (ja) 2024-12-27
EP4316596A3 (en) 2024-04-17
HRP20231514T1 (hr) 2024-03-01
AU2015238264B2 (en) 2020-09-03
CN106536553A (zh) 2017-03-22
HUE047398T2 (hu) 2020-04-28
IL248038B (en) 2020-08-31
HUE064573T2 (hu) 2024-03-28
CN106536553B (zh) 2021-03-12
US11634482B2 (en) 2023-04-25
NZ724649A (en) 2022-07-01
EP3122775A1 (en) 2017-02-01
DK3653644T3 (da) 2023-12-18
KR20160139005A (ko) 2016-12-06
LT3653644T (lt) 2024-01-25
DK3122775T3 (da) 2020-02-03

Similar Documents

Publication Publication Date Title
JP7607498B2 (ja) 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP7270522B2 (ja) 増殖分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体
CA2943694C (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
GB2524552A (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
HK1231096A1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HK1231096B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
BR112016022013B1 (pt) Anticorpos monoclonais que se ligam a gdf-15 humano e kit compreendendo os mesmos
HK1210950B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210406

R150 Certificate of patent or registration of utility model

Ref document number: 6865585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250